Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scinai Immunotherapeutics Ltd. - American Depositary Shares (NQ: SCNI )

3.350 UNCHANGED
Streaming Delayed Price Updated: 12:40 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.350
Bid (Size) 3.100 (1)
Ask (Size) 3.700 (1)
Prev. Close 3.350
Today's Range 3.350 - 3.350
52wk Range 2.230 - 8.920
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary
Via Investor Brand Network
Cases of Parvovirus B19 Spike in the US
Via Investor Brand Network

Performance

YTD
-45.05%
-45.05%
1 Month
-5.10%
-5.10%
3 Month
-3.46%
-3.46%
6 Month
+4.69%
+4.69%
1 Year
-46.91%
-46.91%

More News

Read More
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Strategic Board Appointment
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board
Via Investor Brand Network
New Drug Approach Could Roll Back Pancreatic Cancer Immunotherapy Resistance
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Nine-Month Financial Results and Business Update
Via Investor Brand Network
New Toolkit Launched to Boost Marburg Screening Readiness in the US
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Spotlight Innovative I&I Pipeline and CDMO Services at BIO-Europe 2024
Via Investor Brand Network
Researchers Shine Spotlight on New Barriers to Vaccination
Via Investor Brand Network
Exposures COVID-19
Whooping Cough Prevalence Rises in US as Missed Shots During Pandemic Come Home to Roost
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
Via Investor Brand Network
New Approach Could Boost Effectiveness of Immunotherapies Against Colorectal Cancer
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), EIB Close on Loan Restructuring Agreement
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
Via Investor Brand Network
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024
Via InvestorPlace
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity
Via Investor Brand Network
Australia Launches Novel Immunotherapy Program to Help Babies with Peanut Allergies
Via Investor Brand Network
7 F-Rated Stocks for Your August 2024 Sell List
Via InvestorPlace
Study Highlights Heightened Risk of Diseases Spreading from Animals to Humans
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives PEI Feedback Regarding Development, Preclinical Trial of Anti-IL-17 NanoAb
Via Investor Brand Network
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.